C60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile

International Journal of Pharmaceutics

Volumn 495, Issue 1, 2015, Pages 551-559

  Raza, Kaisar ^a   Thotakura, Nagarani ^a   Kumar, Pramod ^a   Joshi, Mayank ^a   Bhushan, Shashi ^b   Bhatia, Amit ^c   Kumar, Vipin ^a   Malik, Ruchi ^a   Sharma, Gajanand ^d   Guru, Santosh Kumar ^b   Katare, O P ^d  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

^b CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^c LOVELY PROFESSIONAL UNIVERSITY   (India)

^d PANJAB UNIVERSITY   (India)

Author keywords

Bioavailability enhancement; Buckminsterfullerene; Drug clearance; Drug delivery; Enhanced cytotoxicity; MCF 7; MDA MB 231; One compartment open body model

Indexed keywords

DOCETAXEL; FULLERENE DERIVATIVE; ANTINEOPLASTIC AGENT; DRUG CARRIER; FULLERENE C60; TAXOID;

ACYLATION; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER CELL LINE; CARBON NUCLEAR MAGNETIC RESONANCE; CARBOXYLATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RELEASE; ELIMINATION HALF-LIFE; ERYTHROCYTE; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MCF 7 CELL LINE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; ULTRAVIOLET SPECTROSCOPY; ZETA POTENTIAL; ANIMAL; APOPTOSIS; CHEMISTRY; MEDICINAL CHEMISTRY; METABOLIC CLEARANCE RATE; PROCEDURES; SURFACE PROPERTY; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG LIBERATION; FULLERENES; HUMANS; MCF-7 CELLS; METABOLIC CLEARANCE RATE; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TAXOIDS; TISSUE DISTRIBUTION;

EID: 84942540709     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.09.016     Document Type: Article

References (42)

1. S. Andreev, D. Purgina, E. Bashkatova, A. Garshev, A. Maerle, I. Andreev, N. Osipova, N. Shershakova, and M. Khaitov Study of fullerene aqueous dispersion prepared by novel dialysis method: simple way to fullerene aqueous solution Fullerenes Nanotubes Carbon Nanostruct. 23 2015 792 800 10.1080/1536383X.2014.998758
2. H. Aoshima, Y. Saitoh, S. Ito, S. Yamana, and N. Miwa Safety evaluation of highly purified fullerenes (HPFs): based on screening of eye and skin damage J. Toxicol. Sci. 34 2009 555 562 10.2131/jts.34.555
3. S. Arora, H. Kaur, R. Kumar, R. Kaur, D. Rana, C.S. Rayat, I. Kaur, S.K. Arora, P. Bubber, and L.M. Bharadwaj In vitro cytotoxicity of multiwalled and single-walled carbon nanotubes on human cell lines Fullerenes Nanotubes Carbon Nanostruct. 23 2015 377 382 10.1080/1536383X.2013.812638
4. S. Arora, R. Kumar, H. Kaur, C.S. Rayat, I. Kaur, S.K. Arora, J. Srivastava, and L.M. Bharadwaj Translocation and Toxicity of docetaxel multi-walled carbon nanotube conjugates in mammalian breast cancer cells J. Biomed. Nanotechnol. 10 2014 3601 3609 10.1166/jbn.2014.1875
5. S. Arora, R. Saharan, H. Kaur, I. Kaur, P. Bubber, and L.M. Bharadwaj Attachment of docetaxel to multiwalled carbon nanotubes for drug delivery applications Adv. Sci. Lett. 17 2012 70 75 10.1166/asl.2012.4251
6. Z. Badri, C. Foroutan-Nejad, and P. Rashidi-Ranjbar A theoretical survey on the D7d [84] fullerene, a fullerene with two heptagon rings Comput. Theor. Chem. 1009 2013 103 107 10.1016/j.comptc.2013.01.005
7. Y. Cho, J. Lee, S. Lee, K. Huh, and K. Park Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles J. Controlled Release 97 2004 249 257 10.1016/j.jconrel.2004.03.013
8. J. Crown Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience Oncologist 9 2004 24 32 10.1634/theoncologist.9-suppl-2-24
9. S.H. Curry Applied biopharmaceutics and pharmacokinetics Leon Shargel B. Andrew, C. Yu, Biopharmaceutics and Drug Disposition vol. 3 1982 Appleton-Century-Crofts New York 287 289 10.1002/bdd.2510030313
10. 60 Sci. Rep. 3 2013 2094 10.1038/srep02094
11. K.L. Hennenfent, and R. Govindan Novel formulations of taxanes: a review. Old wine in a new bottle? Ann. Oncol. 17 2006 735 749 10.1093/annonc/mdj100
12. R.S. Herbst, and F.R. Khuri Mode of action of docetaxel - a basis for combination with novel anticancer agents Cancer Treat. Rev. 29 2003 407 415 10.1016/S0305-7372(03)97-5
13. Z. Huang, S. Hua, Y. Yang, and J. Fang Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion Acta Pharmacol. Sin. 2008 1094 1102 10.1111/j.1745-7254.2008.00829.x
14. S. Kumar, A. Kumar, A.S. Pathania, S.K. Guru, S. Jada, P.R. Sharma, S. Bhushan, A.K. Saxena, H.M.S. Kumar, and F. Malik Tiron and trolox potentiate the autophagic cell death induced by magnolol analog Ery5 by activation of Bax in HL-60 cells Apoptosis 18 2013 605 617 10.1007/s10495-013-0805-y
15. Y.C. Kuo, and H.F. Ko Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles Biomaterials 34 2013 4818 4830 10.1016/j.biomaterials.2013.03.013
16. J.H. Liu, A.T. Wu, M.H. Huang, C.W. Wu, and W.S. Chung The syntheses of pyrazino-containing sultines and their application in Diels-Alder reactions with electron-poor olefins and [60]fullerene J. Org. Chem. 65 2000 3395 3403 10.1021/jo9918448
17. Z. Markovic, and V. Trajkovic Biomedical potential of the reactive oxygen species generation and quenching by fullerenes (C60) Biomaterials 29 2008 3561 3573 10.1016/j.biomaterials.2008.05.005
18. J.J. Moes, S.L.W. Koolen, A.D.R. Huitema, J.H.M. Schellens, J.H. Beijnen, and B. Nuijen Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001) Int. J. Pharm. 420 2011 244 250 10.1016/j.ijpharm.2011.08.041
19. T. Mori, H. Takada, S. Ito, K. Matsubayashi, N. Miwa, and T. Sawaguchi Preclinical studies on safety of fullerene upon acute oral administration and evaluation for no mutagenesis Toxicology 225 2006 48 54 10.1016/j.tox.2006.05.001
20. D.L. Morse, H. Gray, C.M. Payne, and R.J. Gillies Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells Mol. Cancer Ther. 4 2005 1495 1504 10.1158/1535-7163.MCT-05-0130
21. P. Mroz, G.P. Tegos, H. Gali, T. Wharton, T. Sarna, and M.R. Hamblin Photodynamic therapy with fullerenes Photochem. Photobiol. Sci. 6 2007 1139 1149 10.1039/b711141j
22. H.-Y. Park, I.-H. Song, J.-H. Kim, and W.-S. Kim Preparation of thermally denatured albumin gel and its pH-sensitive swelling Int. J. Pharm. 175 1998 231 236 10.1016/S0378-5173(98)289-0
23. ®) Cancer Treat. Rev. 19 1993 351 386 10.1016/0305-7372(93)90010-O
24. D.P. Petrylak, C.M. Tangen, M.H.A. Hussain, P.N. Lara, J.A. Jones, M.E. Taplin, P.A. Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, and E.D. Crawford Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N. Engl. J. Med. 351 2004 1513 1520 10.1056/NEJMoa041318
25. P. Potier Synthesis of the antitumor dimeric indole alkaloids from catharanthus species (vinblastine group) J. Nat. Prod. 43 1980 72 86 10.1021/np50007a004
26. S. Prylutska, I. Grynyuk, O. Matyshevska, Y. Prylutskyy, M. Evstigneev, P. Scharff, and U. Ritter C60 fullerene as synergistic agent in tumor-inhibitory doxorubicin treatment Drugs R. D. 14 2014 333 340 10.1007/s40268-014-0074-4
27. B.M. Rao, A. Chakraborty, M.K. Srinivasu, M.L. Devi, P.R. Kumar, K.B. Chandrasekhar, A.K. Srinivasan, A.S. Prasad, and J. Ramanatham A stability-indicating HPLC assay method for docetaxel J. Pharm. Biomed. Anal. 41 2006 676 681 10.1016/j.jpba.2006.01.011
28. M.A. Rizvi, S. Guru, T. Naqvi, M. Kumar, N. Kumbhar, S. Akhoon, S. Banday, S.K. Singh, S. Bhushan, G. Mustafa Peerzada, and B.A. Shah An investigation of in vitro cytotoxicity and apoptotic potential of aromatic diselenides Bioorg. Med. Chem. Lett. 24 2014 3440 3446 10.1016/j.bmcl.2014.05.075
29. A. Ruiz, M. Suárez, N. Martin, F. Albericio, and H. Rodríguez Morphological characterization of fullerene-androsterone conjugates Beilstein J. Nanotechnol. 5 2014 374 379 10.3762/bjnano.5.43
30. J.H. Schellens, M.M. Malingré, C.M.F. Kruijtzer, H. Bardelmeijer, O. van Tellingen, A.H. Schinkel, and J.H. Beijnen Modulation of oral bioavailability of anticancer drugs: from mouse to man Eur. J. Pharm. Sci. 12 2000 103 110 10.1016/S0928-0987(00)153-6
31. R.F. Schinazi, R. Sijbesma, G. Srdanov, C.L. Hill, and F. Wudl Synthesis and virucidal activity of a water-soluble, configurationally stable, derivatized C60 fullerene Antimicrob. Agents Chemother. 37 1993 1707 1710 10.1128/AAC.37.8.1707
32. J. Shi, X. Yu, L. Wang, Y. Liu, J. Gao, J. Zhang, and R. Ma PEGylated fullerene/iron oxide nanocomposites for photodynamic therapy, targeted drug delivery and MR imaging Biomaterials 34 2013 9666 9677 10.1016/j.biomaterials.2013.08.049
33. J. Shi, H. Zhang, L. Wang, L. Li, H. Wang, Z. Wang, Z. Li, C. Chen, L. Hou, C. Zhang, and Z. Zhang PEI-derivatized fullerene drug delivery using folate as a homing device targeting to tumor Biomaterials 34 2013 251 261 10.1016/j.biomaterials.2012.09.039
34. B. Singh, S. Beg, S. Lohan, and K. Raza Carbon nano tubes (CNTs) and their application in drug delivery systems B.O.P.K. Singh, Recent Trends Biotechnology vol. 8 2015 Studium Press Houston LLC ISBN: 9781626990234
35. V.T. Thakkar, Shah P. a, T.G. Soni, M.Y. Parmar, M.C. Gohel, and T.R. Gandhi Goodness-of-fit model-dependent approach for release kinetics of levofloxacin hemihydrates floating tablet Dissolution Technol. 16 2009 35 39
36. A. Trpkovic, B. Todorovic-Markovic, and V. Trajkovic Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress Arch. Toxicol. 86 2012 1809 1827 10.1007/s00204-012-0859-6
37. E. Tsakalozou, A.M. Eckman, and Y. Bae Combination effects of docetaxel and doxorubicin in hormone-refractory prostate cancer cells Biochem. Res. Int. 2012 2012 832059 10.1155/2012/832059
38. L. Wang, M. Zhang, N. Zhang, J. Shi, H. Zhang, M. Li, C. Lu, and Z. Zhang Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes Int. J. Nanomed. 6 2011 2641 2652 10.2147/IJN.S24167
39. K.L. Yap, X. Liu, J.C. Thenmozhiyal, and P.C. Ho Characterization of the 13-cis-retinoic acid/cyclodextrin inclusion complexes by phase solubility, photostability, physicochemical and computational analysis Eur. J. Pharm. Sci. 25 2005 49 56 10.1016/j.ejps.2005.01.021
40. D.A. Yardley, H.A. Burris, C.P. Farley, J.H. Barton, N.W. Peacock, D.R. Spigel, F.A. Greco, and J.D. Hainsworth A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer Clin. Breast Cancer 8 2008 242 248 10.3816/CBC.2008.n.027
41. J.A. Yared, and K.H.R. Tkaczuk Update on taxane development: new analogs and new formulations Drug Des. Dev. Ther. 6 2012 371 384 10.2147/DDDT.S28997
42. 70 in toluene, o-xylene and carbon disulfide at various temperatures Fullerine Sci. Technol. 5 1997 285 290 10.1080/15363839708011990